Phaseline

Targets › CYP11B2

CYP11B2 (Cytochrome P450 11B2, mitochondrial): drug programs, companies and trials

4 programs from 3 companies in 8 trials: 5 Phase 3, 2 Phase 2, 1 Phase 1; Cardiovascular, Metabolic and endocrine, Genitourinary; next expected readout Dec 2026.

A cytochrome P450 monooxygenase that catalyzes the biosynthesis of aldosterone, the main mineralocorticoid in the human body responsible for salt and water homeostasis, thus involved in blood pressure regulation, arterial hypertension, and the development of heart failure. Catalyzes three sequential oxidative reactions of 11-deoxycorticosterone (21-hydroxyprogesterone), namely 11-beta hydroxylation, followed by two…. (UniProt, P19099)

Open in Phaseline: the race on CYP11B2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
AstraZenecabaxdrostat
Aldosterone synthase inhibitor
CYP11B2Phase 3Primary Hyperaldosteronism; Uncontrolled Hypertension; Chronic Kidney Disease and HypertensionDec 2026
Mineralys Therapeuticslorundrostat
Aldosterone synthase inhibitor
CYP11B2Phase 3HypertensionMay 2027
University Medical Center Groningenvicadrostat
Aldosterone synthase inhibitor
CYP11B2Phase 2CKDFeb 2028
University Medical Center Groningen[18F]CETO tracer
PET tracer with high specificity for steroidogenic enzymes CYP11B1 and CYP11B2 in adrenal
CYP11B1, CYP11B2Phase 1Primary AldosteronismMay 2027

Conditions

Chronic Kidney Disease and Hypertension (3) Primary Aldosteronism (1) Primary Hyperaldosteronism (1) Uncontrolled Hypertension (1) Hypertension (1) CKD (1)

Modalities

small molecule (4)

Companies

University Medical Center Groningen (2) AstraZeneca (1) Mineralys Therapeutics (1)

Related targets

CYP11B1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.